The major contributing factors to the failure of the trials were the sub-optimal clinical design, including the lack of patient selection criteria for those with IDO1 positive tumour(s) who would likely benefit from this targeted inhibition and inadequate understanding of the dynamics between the KYN pathway with other cancer-associated signalling pathways12. The gene discussed is IDO1; the disease is neoplasm.